Reported about 6 hours ago
BioNTech announced that its Q2 revenues soared to 261 million euros, more than doubling from the previous year, due to heightened sales from its COVID-19 vaccine partnership with Pfizer. The company reported a reduced net loss of 387 million euros compared to 808 million euros a year prior, aided by lower operating expenses. Despite the positive revenue growth, BioNTech lowered its 2025 revenue forecast to between 1.7 billion and 2.2 billion euros. Additionally, the firm is expanding its portfolio through the acquisition of CureVac and a significant deal with Bristol Myers Squibb for cancer therapies.
Source: YAHOO